Imunon
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
997 Lenox Dr Ste 100, Lawrenceville, New...Phone Number
(609) 896-9100Website
www.imunon.comRevenue
-Stock Symbol
IMNNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Imunon
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnessing natural biological mechanisms to generate durable therapeutic responses. Through its integrated research, development, and manufacturing capabilities, Imunon advances novel immunology-driven medicines designed to address unmet medical needs and improve patient outcomes across a broad range of serious health conditions.Explore more
Imunon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imunon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Imunon has new funding data
Congratulate Masked Content for being promoted to Masked Content at Imunon
Check if Imunon has recently received funding, and reach out quickly before it becomes old news!
Click to see if Imunon had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Imunon is spiking on competitors!
Earning: See what the market has to say on Imunon recently announced quarterly report
Product Launch: Get notified when Imunon launches new products
Imunon, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Imunon as Masked Content
Find 3 more new buyers
Compare Similar Companies to Imunon
Compare insights from companies similar to Imunon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imunon is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Imunon is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Imunon.
Imunon financials insights
Gather financial insights about Imunon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$10M
Imunon Tech Stack
A closer look at the technologies used by Imunon
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Earnings
Imunon has reported research and development expenses of $7.8 million for fiscal year 2025, a significant decrease compared to 2024, primarily due to the completion of the OVATION 2 study, optimization of the MRD study, and focused spending on OVATION 3 manufacturing and startup activities.
Earnings, Research & Development, Accounting, Financial Reporting, Finance
Project
Events, Medical Research, Pharmaceuticals, Clinical Operations
Imunon News & Media
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, August 11, 2026 to discuss financial results for the second quarter ended June 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing PhIMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
LAWRENCEVILLE, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) (“IMUNON” or “the Company”), a clinical-stage biotechnology company developing its novel DNA-mediated immunotherapies, today is providing a progress update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer. Since initiating the trial, the Company has observed rapid site activation and an enrollment rate that is exceeding its forecast. The trial advanced froIMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanismIMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Imunon
Sign Up For FreeTo access detailed company insights
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnes... Read More
